These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33612191)

  • 1. Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
    Khan A; Khan Q; Kolb E
    J Subst Abuse Treat; 2021 Apr; 123():108256. PubMed ID: 33612191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access.
    Kolb E; Rueth M
    J Opioid Manag; 2021; 17(7):77-86. PubMed ID: 34520029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of an emergency department peer navigator (EDPN) program in improving clinical outcomes and healthcare utilization in an urban setting.
    Santos C; Ramdin C; Becceril J; Al Kik B; Jefri M; Nelson L
    Am J Emerg Med; 2023 Jun; 68():10-16. PubMed ID: 36905880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
    Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
    J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
    Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
    Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study.
    Suzuki J; Zinser J; Klaiber B; Hannon M; Grassi H; Spinosa M; Ramirez A; Issa M; Chin Feman SP
    Subst Abus; 2015; 36(2):166-9. PubMed ID: 25738320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.
    Schuman-Olivier Z; Hoeppner BB; Weiss RD; Borodovsky J; Shaffer HJ; Albanese MJ
    Drug Alcohol Depend; 2013 Oct; 132(3):580-6. PubMed ID: 23688843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
    Noe SR; Keller T
    J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
    Smith A; Hansen J; Colvard M
    J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment retention of an emergency department initiated medication for opioid use disorder program.
    Reuter QR; Santos AD; McKinnon J; Gothard D; Jouriles N; Seaberg D
    Am J Emerg Med; 2022 May; 55():98-102. PubMed ID: 35304308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "It's a place that gives me hope": A qualitative evaluation of a buprenorphine-naloxone group visit program in an urban federally qualified health center.
    Lai S; Li E; Silverio A; DeBates R; Kelly EL; Weinstein LC
    Subst Abus; 2021; 42(4):858-864. PubMed ID: 33492204
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder.
    Morgan JR; Quinn EK; Chaisson CE; Ciemins E; Stempniewicz N; White LF; Larochelle MR
    J Subst Abuse Treat; 2022 Feb; 133():108540. PubMed ID: 34148756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
    Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
    J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.
    Mahone A; Enich M; Treitler P; Lloyd J; Crystal S
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):606-617. PubMed ID: 37506336
    [No Abstract]   [Full Text] [Related]  

  • 17. "In their mind, they always felt less than": The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention.
    Anvari MS; Kleinman MB; Massey EC; Bradley VD; Felton JW; Belcher AM; Magidson JF
    J Subst Abuse Treat; 2022 Jul; 138():108721. PubMed ID: 35067397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study.
    Carter J; Li Z; Chen H; Greiner M; Bush C; Bhattacharya D; Poley S; Sachdeva N; Crowder JC; Feigal J
    Addict Sci Clin Pract; 2022 Nov; 17(1):60. PubMed ID: 36335381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine Practice.
    Cope K; DeMicco J; Salib J; Michael M; Yakoub P; Daoud K; Cope R
    J Addict Med; 2022 Nov-Dec 01; 16(6):716-721. PubMed ID: 35913992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.